Sunshine Biopharma Inc. financial data

Symbol
SBFM, SBFMW on Nasdaq
Location
333 Las Olas Way, Cu4 Suite 433, Fort Lauderdale, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 437 % -9.14%
Quick Ratio 207 % +42.6%
Debt-to-equity 28.2 % +10.9%
Return On Equity -25 % -39.5%
Return On Assets -19.5 % -36.5%
Operating Margin -17.5 % -17.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.91M shares +145%
Common Stock, Shares, Outstanding 4.56M shares +128%
Entity Public Float 22.6M USD +111%
Common Stock, Value, Issued 4.56K USD +128%
Weighted Average Number of Shares Outstanding, Basic 4.56M shares +259%
Weighted Average Number of Shares Outstanding, Diluted 3.6M shares +8714%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 37.3M USD +13.2%
Cost of Revenue 6.34M USD +13.9%
Research and Development Expense 680K USD -57.5%
General and Administrative Expense 18.8M USD +25.4%
Operating Income (Loss) -6.52M USD -33.5%
Nonoperating Income (Expense) 15.8K USD -98%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -6.51M USD -58.3%
Income Tax Expense (Benefit) -516K USD -552%
Net Income (Loss) Attributable to Parent -5.99M USD -41.8%
Earnings Per Share, Basic 4 USD/shares +79.8%
Earnings Per Share, Diluted -0.82 USD/shares +98.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.7M USD -52.7%
Accounts Receivable, after Allowance for Credit Loss, Current 3.59M USD
Inventory, Net 14.1M USD +43.2%
Assets, Current 28M USD +7.64%
Property, Plant and Equipment, Net 598K USD +1.23%
Operating Lease, Right-of-Use Asset 820K USD +51.5%
Intangible Assets, Net (Excluding Goodwill) 2.01M USD -31.7%
Goodwill 0 USD
Assets 31.5M USD +4.76%
Accounts Payable, Current 6.14M USD +47.6%
Liabilities, Current 6.65M USD +46.9%
Operating Lease, Liability, Noncurrent 637K USD +44.6%
Liabilities 7.29M USD +45.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -321K USD -290%
Retained Earnings (Accumulated Deficit) -72.9M USD -8.96%
Stockholders' Equity Attributable to Parent 24.2M USD -3.36%
Liabilities and Equity 31.5M USD +4.76%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.71M USD +46.2%
Net Cash Provided by (Used in) Financing Activities 338K USD -93.7%
Net Cash Provided by (Used in) Investing Activities -176K USD +73.7%
Common Stock, Shares Authorized 3B shares 0%
Common Stock, Shares, Issued 4.56M shares +128%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.31M USD -23.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 6.97M USD +8.91%
Depreciation 222K USD +48.3%
Payments to Acquire Property, Plant, and Equipment 7.49K USD -88.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.48M USD -52.1%
Property, Plant and Equipment, Gross 1.06M USD
Operating Lease, Liability, Current 218K USD +87.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 201K USD +82.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 212K USD +82.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 191K USD +83.6%
Deferred Tax Assets, Operating Loss Carryforwards 6.46M USD +22.4%
Preferred Stock, Shares Authorized 30M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 181K USD +84.8%
Additional Paid in Capital 97.4M USD +6.15%
Amortization of Intangible Assets 38.4K USD
Depreciation, Depletion and Amortization 64.8K USD +52%
Deferred Tax Assets, Net of Valuation Allowance 482K USD +173%
Interest Expense 145K USD +115%
Preferred Stock, Par or Stated Value Per Share 0.1 USD/shares